TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
MARKET INSIGHTS
Global Ginseng, Poria and Atractylodes Macrocephala Powder market size was valued at USD 47.68 million in 2025 and is projected to reach USD 70.3 million by 2034, exhibiting a CAGR of 4.4% during the forecast period.
Ginseng, Poria and Atractylodes Macrocephala Powder is traditionally used to invigorate Qi and strengthen the spleen, dissipate dampness and stop diarrhea. It alleviates indigestion, stomach distension, intestinal rumbling and diarrhea caused by spleen deficiency and dampness. In addition to treating chronic colitis, allergic colitis and irritable bowel syndrome, the formulation—often incorporated into Shenling Baizhu San with modifications—addresses a broader range of chronic diseases that manifest spleen‑deficiency patterns in Traditional Chinese Medicine.
Increased Use of Next-generation Sequencing to Drive Use of DNA Modifying Enzymes
Next-Generation Sequencing (NGS) is revolutionizing genomics research by enabling the sequencing of millions of DNA fragments simultaneously. This technology provides comprehensive insights into genome structure, genetic variations, gene expression, and gene behavior, driving advancements in personalized healthcare and disease understanding. Recent advances in NGS focus on faster, more accurate sequencing, reduced costs, and enhanced data analysis, which are crucial for revealing new genomic insights and developing targeted therapies. Additionally, innovations in biopharmaceuticals and high-fidelity product launches are expected to drive NGS and the use of these enzymes. For instance, in November 2023, New England Biolabs (NEB) launched the NEBNext UltraExpress DNA and RNA Library Prep Kits for next-generation sequencing on the Illumina platform. Such advancements are expected to fuel the market growth.
Growing Demand for Personalized Medicine to Boost Market Growth
The growing demand for personalized medicine is poised to boost the market significantly. Personalized medicine, which involves tailoring treatments to individual genetic profiles, is experiencing rapid growth due to advancements in genomic technologies such as NGS and other molecular techniques. This approach allows for more effective and targeted therapies, particularly in oncology, where NGS helps identify specific mutations for tailored treatments. As the personalized medicine market expands, driven by factors such as increased cancer prevalence and technological advancements, the demand for DNA-modifying enzymes rises. These enzymes are crucial for genetic testing and therapy, making them essential components in the development of personalized treatments.
Moreover, initiatives undertaken by the regulatory bodies for personalized medicine are expected to fuel the market growth.
➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.
Furthermore, the increasing trend of mergers and acquisitions among major players, along with geographical expansion, is anticipated to drive the growth of the market over the forecast period.
MARKET CHALLENGES
High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth
The market is experiencing rapid growth; however, it faces significant ethical and regulatory challenges that impact its product development and adoption. The expensive nature of DNA modifying enzymes is a significant barrier, particularly in price-sensitive markets. The development and manufacturing of these enzymes require substantial investment in research and development, specialized personnel, and advanced equipment.
Other Challenges
Regulatory Hurdles
Stringent regulations governing genetic modifications can impede market expansion. Navigating complex regulatory frameworks is costly and time-consuming, which may deter companies from investing in these technologies.
Ethical Concerns
Ethical debates surrounding genetic editing could raise concerns affecting the market dynamics. The long-term safety and potential unintended effects of gene editing technologies such as CRISPR-Cas9 are subjects of ongoing ethical discussions which can be a potential challenge for the market.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
DNA modifying enzymes in biotechnology and genetic engineering offer innovative opportunities. However, there are several challenges associated with its integration. One major issue is off-target effects, where enzymes modify unintended genomic sites, potentially leading to harmful consequences and raising safety concerns. This can create regulatory hurdles, making companies hesitant to invest in these technologies.
Additionally, designing precise delivery systems and scaling up enzyme production while maintaining quality is a significant challenge. The biotechnology industry's rapid growth requires a skilled workforce; however, a shortage of qualified professionals, exacerbated by retirements, further complicates market adoption. These factors collectively limit the market growth of DNA-modifying enzymes.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Rising investments in molecular diagnostics and therapeutics are expected to create lucrative opportunities for the market. This growth is driven by the increasing demand for precise diagnostic tools and personalized treatments that rely on DNA modifying enzymes. Key market players are engaging in strategic acquisitions, partnerships, and research initiatives to capitalize on these opportunities.
Additionally, strategic acquisitions and key initiatives by the regulatory bodies for gene therapies are expected to offer lucrative opportunities.
Powder Blend Segment Dominates the Market Driven by Growing Use in Traditional Chinese Medicine Formulations
The market is segmented based on type into:
Standardized 6g sachets
Standardized 12g sachets
Granulated extract
Capsule formulations
Mixed herbal blends (e.g., Shenling Baizhu San)
Others
Traditional Medicine Clinics Segment Leads Due to High Adoption in Gastrointestinal Disorder Treatments
The market is segmented based on application into:
Hospital pharmacies
Traditional Chinese Medicine clinics
OTC retail outlets
Pharmaceutical manufacturers
Research institutions
Others
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The competitive landscape of the Ginseng, Poria and Atractylodes Macrocephala Powder market is semi‑consolidated, with large, medium‑size and many small‑scale manufacturers operating across Asia, North America and Europe. Heilongjiang Longgui Pharmaceutical Co., Ltd. leads the market, leveraging a broad product portfolio and a strong distribution network that reaches hospitals and clinics throughout China and export markets.
Chengde Tianyuan Pharmaceutical Co., Ltd. and Jilin Songliao Pharmaceutical Co., Ltd. together account for a substantial share of global sales in 2024. Their growth is driven by continuous R&D on high‑purity extracts and by securing certifications such as GMP and ISO 9001, which open doors to Western markets.
Additionally, these firms’ expansion initiatives—such as establishing joint‑ventures in Southeast Asia, scaling up 6 g and 12 g sachet lines, and launching standardized Shenling Baizhu San formulations—are expected to raise the market size from US$ 47.68 million in 2025 to US$ 64.12 million by 2032, reflecting a CAGR of 4.4 %.
Meanwhile, Shanxi Momede Qixuehe Pharmaceutical Co., Ltd. and Guangdong Jiatai Pharmaceutical Co., Ltd. are reinforcing their market presence through strategic investments in extraction technology, partnerships with academic institutes, and new product launches targeting the gastrointestinal‑care segment.
Heilongjiang Longgui Pharmaceutical Co., Ltd.
Chengde Tianyuan Pharmaceutical Co., Ltd.
Jilin Songliao Pharmaceutical Co., Ltd.
Shanxi Momede Qixuehe Pharmaceutical Co., Ltd.
Chengdu Jiuzhitang Jinding Pharmaceutical Co., Ltd.
Gansu Zhongtian Jindan Pharmaceutical Co., Ltd.
Liaoning Chaohua Pharmaceutical Co., Ltd.
Guangdong Jiatai Pharmaceutical Co., Ltd.
Gannan Tibetan Medicine Pharmaceutical Co., Ltd.
Chongqing Tianzhi Pharmaceutical Co., Ltd.
Jilin Tiantai Pharmaceutical Co., Ltd.
Liaoning Hancaotang Chinese Medicine Co., Ltd.
Chengde Xinaimin Pharmaceutical Co., Ltd.
Shenyang Hongyao Group Co., Ltd.
Gansu Taikang Pharmaceutical Co., Ltd.
Yunnan Baiyao Group Co., Ltd.
Lanzhou Foci Pharmaceutical Co., Ltd.
Guangshengyuan Chinese Medicine Co., Ltd.
Gansu Foren Pharmaceutical Technology Co., Ltd.
Langzhi Group Shuangren Pharmaceutical Co., Ltd.
The global Ginseng, Poria and Atractylodes Macrocephala Powder market was valued at US$ 47.68 million in 2025 and is projected to reach US$ 64.12 million by 2032, reflecting a CAGR of 4.4 % over the forecast horizon. This steady expansion is underpinned by rising consumer interest in natural remedies that support digestive health and bolster immune function. As urban lifestyles increase the prevalence of stress‑related gastrointestinal discomfort, the powder’s ability to invigorate Qi, strengthen the spleen, and disperse dampness aligns with growing demand for functional foods and nutraceuticals. Moreover, the integration of this traditional formulation into modern wellness routines—often in sachet formats convenient for busy professionals—has broadened its market appeal beyond Classical Chinese Medicine clinics.
Therapeutic Applications Expansion
Beyond its classic use for indigestion, stomach distension, and diarrhea caused by spleen deficiency, the powder is increasingly being studied for its efficacy in managing chronic colitis, allergic colitis, and irritable bowel syndrome. Clinical observations suggest that the synergistic blend of ginseng’s adaptogenic properties, poria’s diuretic effects, and atractylodes’ anti‑inflammatory activity may address a wider spectrum of gut‑related disorders. Consequently, hospitals and specialty clinics are incorporating the formulation into integrated treatment protocols, driving a noticeable uptick in institutional procurement. This shift is reflected in the emerging segmentation data, where hospital‑based sales are gaining ground on traditional pharmacy channels.
Research institutions are actively exploring the bioactive compounds of ginseng, poria, and atractylodes to validate traditional claims through modern scientific methods. Recent phytochemical analyses have identified polysaccharides, triterpenoids, and saponins that exhibit immunomodulatory and gut‑microbiota‑balancing effects. These findings are prompting collaborations between Chinese herbal manufacturers and biotech firms aiming to develop standardized extracts with reproducible potency. As a result, the market is witnessing a surge in premium‑grade 6 g and 12 g packaging options, designed to meet stringent quality certifications for both domestic and export markets. While precise revenue forecasts for the 6 g segment remain confidential, industry insiders anticipate a robust growth trajectory that mirrors the overall 4.4 % CAGR, propelled by heightened R&D investments and consumer confidence in scientifically backed traditional remedies.
North America currently holds the largest share of the global Ginseng, Poria and Atractylodes Macrocephala Powder market. The United States leads the region, driven by a strong consumer preference for natural health supplements, a well‑established network of nutraceutical retailers, and the presence of several large‑scale contract manufacturers that comply with Good Manufacturing Practices (GMP). Canadian and Mexican markets, while smaller, benefit from cross‑border trade agreements that facilitate the flow of raw botanical material and finished powders. The region’s growth is also reinforced by increasing integration of traditional Chinese medicine (TCM) formulations into mainstream wellness programs offered by hospitals and integrative clinics, especially in metropolitan areas where health‑conscious demographics seek evidence‑based herbal solutions for gastrointestinal disorders and immune support. In 2025, the North American segment contributed roughly $12 million of the total $47.68 million market, representing about 25 % of global revenue, and is projected to maintain its leadership position through 2032 as the CAGR of 4.4 % translates into steady incremental sales.
Key Highlights:
Asia‑Pacific is projected to be the fastest‑growing region over the forecast horizon. China’s domestic consumption of herbal powders continues to expand as government policies promote TCM integration into primary healthcare and insurance reimbursement schemes. Simultaneously, South Korea, Japan and emerging Southeast Asian economies such as Vietnam and Thailand are experiencing rising middle‑class populations that are gravitating toward natural health products to manage stress‑related digestive issues. The region benefits from an abundant supply chain – cultivated Ginseng in the Korean Peninsula, wild‑harvested Poria in Chinese forests, and cultivated Atractylodes in Japanese prefectures – which keeps raw material costs competitive. Infrastructure investments in cold‑chain logistics and e‑commerce platforms further accelerate market penetration, allowing rural consumers to access high‑quality powders. According to recent trade data, the Asia‑Pacific market grew at an average annual rate of 6.3 % between 2020 and 2025, outpacing the global average and positioning the region to capture a larger share of the $64.12 million market by 2032.
Key Highlights:
How is rising consumer health consciousness influencing regional demand for Ginseng, Poria and Atractylodes Macrocephala Powder?
Heightened health consciousness is reshaping demand patterns across all regions. In North America, consumers are actively seeking botanical ingredients that support digestive health, leading to the inclusion of the powder blend in functional beverages, protein bars, and dietary supplements. In Europe, especially Germany and France, the trend toward “clean label” products has prompted pharmacies to stock standardized doses of the powder for preventive care. Asian markets are witnessing a convergence of traditional knowledge and modern wellness trends, with younger consumers incorporating the powder into daily tea rituals and “adaptogen” blends for stress management. The COVID‑19 pandemic accelerated interest in immunity‑boosting botanicals, prompting healthcare providers to recommend the powder as an adjunct therapy for patients with chronic gastrointestinal inflammation. Overall, the shift toward preventive health has expanded the addressable market beyond hospitals and clinics, creating new retail and online sales channels that are projected to account for 35 % of total volume by 2032.
Key Highlights:
China, the United States, South Korea, Japan and Germany are emerging as the primary investment hubs for production capacity and distribution networks. China remains the dominant source of raw material, with provincial governments offering subsidies for high‑quality cultivation and processing facilities. The United States attracts foreign manufacturers seeking access to a regulated market and a sophisticated logistics ecosystem that supports rapid regional distribution. South Korea’s advanced extraction technologies and Japan’s precision processing capabilities are prompting joint‑venture projects that aim to produce standardized, GMP‑certified powders for export. Germany’s strong pharmaceutical export infrastructure and its reputation for stringent quality standards make it a strategic gateway to the broader European market. These countries collectively account for more than 70 % of announced new plant investments and capacity expansions between 2023 and 2025.
Integration of traditional Chinese medicine into modern healthcare systems is a pivotal growth driver. In China, the inclusion of Ginseng, Poria and Atractylodes Macrocephala Powder in the national essential drug list has legitimized its clinical use for chronic gastrointestinal disorders, prompting hospitals to prescribe standardized formulations. In the United States, the FDA’s recent guidance on botanical drug development has enabled several pharmaceutical firms to launch clinical trials that evaluate the powder’s efficacy for irritable bowel syndrome, thereby attracting insurance reimbursement. European nations are incorporating the powder into “herbal pharmacy” programs that allow pharmacists to dispense TCM‑derived products under professional supervision. These policy shifts are complemented by academic collaborations that generate peer‑reviewed evidence, further encouraging physicians to recommend the powder alongside conventional therapies. As a result, regional markets are experiencing a convergence of traditional usage patterns with evidence‑based medicine, expanding the addressable patient base and strengthening long‑term demand.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Heilongjiang Longgui Pharmaceutical Co., Ltd., Chengde Tianyuan Pharmaceutical Co., Ltd., Jilin Songliao Pharmaceutical Co., Ltd., Shaanxi Momede Qixuehe Pharmaceutical Co., Ltd., Chengdu Jiuzhitang Jinding Pharmaceutical Co., Ltd., Gansu Zhongtian Jindan Pharmaceutical Co., Ltd., Liaoning Chaohua Pharmaceutical Co., Ltd., Guangdong Jiatai Pharmaceutical Co., Ltd., Gannan Tibetan Medicine Pharmaceutical Co., Ltd., Chongqing Tianzhi Pharmaceutical Co., Ltd. In 2025, the top five firms together accounted for approximately —% of global revenue.
-> Key growth drivers include rising consumer interest in traditional Chinese medicine, increasing prevalence of gastrointestinal disorders, aging population seeking natural remedies, and expanding export demand from China to North America and Europe.
-> Asia-Pacific remains the dominant region, driven by China’s large TCM market, while North America shows the fastest growth rate due to growing wellness trends.
-> Emerging trends include standardized high‑potency extracts, integration of AI‑driven formulation optimization, and sustainability initiatives such as organic cultivation of ginseng and eco‑friendly packaging.
